Related Experiment Video

Updated: Jul 27, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Amikacin in the treatment of gram-negative bronchopulmonary infections

M Van Der Straeten, R Pauwels, J Pijck

    The Journal of Infectious Diseases
    |November 1, 1976
    PubMed

    Insights

    Amikacin effectively treated acute gram-negative bronchopulmonary infections in most patients, leading to complete recovery. This study highlights amikacin

    Area of Science:

    • Infectious Diseases
    • Pulmonology
    • Pharmacology

    Background:

    • Acute gram-negative bronchopulmonary infections pose significant treatment challenges.
    • Underlying conditions like bronchocarcinoma and bronchiectasis complicate management.
    • Pseudomonas aeruginosa and Haemophilus influenzae are common causative agents.

    Purpose of the Study:

    • To evaluate the efficacy and safety of intramuscular amikacin in treating acute gram-negative bronchopulmonary infections.
    • To assess the clinical outcomes and potential adverse effects of amikacin therapy.
    • To investigate amikacin absorption and serum level variability.

    Main Methods:

    • Six patients with acute gram-negative bronchopulmonary infections received intramuscular amikacin (15 mg/kg/day) for 10-13 days.
    • Patients had diverse underlying pulmonary conditions.
    • Causative pathogens included Pseudomonas aeruginosa, Haemophilus influenzae, Klebsiella ozaenae, and Enterobacter cloacae.

    Main Results:

    • Five out of six patients achieved complete recovery, with symptom resolution and pathogen eradication.
    • One patient with advanced bronchocarcinoma did not respond and died.
    • No significant abnormalities were observed in liver/renal function or blood counts; reversible nystagmographic changes noted.

    Conclusions:

    • Intramuscular amikacin demonstrates significant efficacy in treating acute gram-negative bronchopulmonary infections.
    • Amikacin is generally well-tolerated, with minimal systemic toxicity observed.
    • Further investigation into amikacin's pharmacokinetic variability may be warranted.

    More Related Videos

    P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

    P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

    Published on: June 15, 2020

    Amikacin Protection Assay for Quantification and Visualization of Escherichia coli Cell Invasion09:22

    Amikacin Protection Assay for Quantification and Visualization of Escherichia coli Cell Invasion

    Published on: July 3, 2026

    Related Concept Videos

    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    Acute Pyelonephritis II: Diagnostic Studies and Management01:28

    Acute Pyelonephritis II: Diagnostic Studies and Management

    Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
    Atypical Pneumonia01:14

    Atypical Pneumonia

    Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
    Inhibitors of Gram-positive Cell Wall Synthesis01:23

    Inhibitors of Gram-positive Cell Wall Synthesis

    Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
    Inhibitors of Bacterial Protein Synthesis01:25

    Inhibitors of Bacterial Protein Synthesis

    Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
    Antifungal Agents01:15

    Antifungal Agents

    Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...